Related Experiment Video
Updated: Mar 9, 2026

10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.7K
Beating the Clock in T-cell Acute Lymphoblastic Leukemia
William L Carroll1, Iannis Aifantis2, Elizabeth Raetz3
1Department of Pediatrics, Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York. william.carroll@nyumc.org.
Abstract:
CDK4/6 inhibition was synergistic with dexamethasone and everolimus but antagonistic with conventional chemotherapy in T-cell acute lymphoblastic leukemia (T-ALL) preclinical models. Cyclin-dependent kinase inhibition in combination with glucocorticoids and mTOR inhibition offers a unique therapeutic opportunity in T-ALL. Clin Cancer Res; 23(4); 873-5. ©2016 AACRSee related article by Pikman et al., p. 1012.

